Showing 7,541 - 7,560 results of 21,342 for search '(( significant decrease decrease ) OR ( significant ((changes decrease) OR (largest decrease)) ))', query time: 0.54s Refine Results
  1. 7541
  2. 7542

    Topology-Driven Mechanical Behavior of Liquid Crystal Elastomers via a Dynamic Mechanical Analyzer by Yan-Ting Lin (9345296)

    Published 2025
    “…Stress relaxation experiments revealed that the synthesized liquid crystal elastomers (LCEs) exhibited significant stress relaxation behavior at 80 °C. Furthermore, when the LCEs were heated to 80 °C without applied stress, their molecular alignment decreased. …”
  3. 7543

    GRADE judgements. by Da Huang (1306407)

    Published 2025
    “…Furthermore, there was no significant difference in the change in resting heart rate (RHR) (MD = 2.04, 95% CI: −2.71–6.78; P = 0.40) between the physical activity group and the control group, but there was a significant difference in the change in maximum heart rate (HR-max) (MD = 6.27, 95% CI: 1.75–10.97, P = 0.007). …”
  4. 7544

    Basic characteristics of the included studies. by Da Huang (1306407)

    Published 2025
    “…Furthermore, there was no significant difference in the change in resting heart rate (RHR) (MD = 2.04, 95% CI: −2.71–6.78; P = 0.40) between the physical activity group and the control group, but there was a significant difference in the change in maximum heart rate (HR-max) (MD = 6.27, 95% CI: 1.75–10.97, P = 0.007). …”
  5. 7545

    The data of meta-analysis. by Da Huang (1306407)

    Published 2025
    “…Furthermore, there was no significant difference in the change in resting heart rate (RHR) (MD = 2.04, 95% CI: −2.71–6.78; P = 0.40) between the physical activity group and the control group, but there was a significant difference in the change in maximum heart rate (HR-max) (MD = 6.27, 95% CI: 1.75–10.97, P = 0.007). …”
  6. 7546

    Risk of bias. by Da Huang (1306407)

    Published 2025
    “…Furthermore, there was no significant difference in the change in resting heart rate (RHR) (MD = 2.04, 95% CI: −2.71–6.78; P = 0.40) between the physical activity group and the control group, but there was a significant difference in the change in maximum heart rate (HR-max) (MD = 6.27, 95% CI: 1.75–10.97, P = 0.007). …”
  7. 7547

    Overall risk of bias assessment. by Da Huang (1306407)

    Published 2025
    “…Furthermore, there was no significant difference in the change in resting heart rate (RHR) (MD = 2.04, 95% CI: −2.71–6.78; P = 0.40) between the physical activity group and the control group, but there was a significant difference in the change in maximum heart rate (HR-max) (MD = 6.27, 95% CI: 1.75–10.97, P = 0.007). …”
  8. 7548

    Funnel plot of VO<sub>2Peak</sub> inclusion studies. by Da Huang (1306407)

    Published 2025
    “…Furthermore, there was no significant difference in the change in resting heart rate (RHR) (MD = 2.04, 95% CI: −2.71–6.78; P = 0.40) between the physical activity group and the control group, but there was a significant difference in the change in maximum heart rate (HR-max) (MD = 6.27, 95% CI: 1.75–10.97, P = 0.007). …”
  9. 7549

    Analysis of subgroups. by Da Huang (1306407)

    Published 2025
    “…Furthermore, there was no significant difference in the change in resting heart rate (RHR) (MD = 2.04, 95% CI: −2.71–6.78; P = 0.40) between the physical activity group and the control group, but there was a significant difference in the change in maximum heart rate (HR-max) (MD = 6.27, 95% CI: 1.75–10.97, P = 0.007). …”
  10. 7550

    Full dataset. by Allison Andrukonis (11846404)

    Published 2025
    “…<div><p>Monitoring and decreasing stress in cats housed in animal shelters is essential for maintaining adequate welfare. …”
  11. 7551
  12. 7552
  13. 7553

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
  14. 7554

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
  15. 7555

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
  16. 7556

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
  17. 7557

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
  18. 7558
  19. 7559

    Causal relationships between allergic diseases and significant declines in lung function: a multivariable Mendelian randomization study by Jiannan Lin (6954983)

    Published 2025
    “…However, in multivariable MR analysis, the independent effects of atopic dermatitis and allergic conjunctivitis on lung function were no longer significant. Only allergic asthma continued to show a significant causal relationship with decreased lung function (OR [95%CI]: 1.019 [1.008–1.030], <i>p</i> < .001).…”
  20. 7560